Natriuretic Peptides and Cardiometabolic Health

Overview

Journal Circ J

Specialty Cardiology & Vascular Diseases

Date 2015 Jun 25

PMID 26103984

Citations 37

Authors

Deepak K Gupta

Thomas J Wang

Affiliations

Soon will be listed here.

Abstract

Natriuretic peptides are cardiac-derived hormones with a range of protective functions, including natriuresis, diuresis, vasodilation, lusitropy, lipolysis, weight loss, and improved insulin sensitivity. Their actions are mediated through membrane-bound guanylyl cyclases that lead to production of the intracellular second-messenger cyclic guanosine monophosphate. A growing body of evidence demonstrates that genetic and acquired deficiencies of the natriuretic peptide system can promote hypertension, cardiac hypertrophy, obesity, diabetes mellitus, the metabolic syndrome, and heart failure. Clinically, natriuretic peptides are robust diagnostic and prognostic markers, and augmenting natriuretic peptides is a target for therapeutic strategies in cardiometabolic disease. This review will summarize current understanding and highlight novel aspects of natriuretic peptide biology.

Citing Articles

Integrative analysis of candidate MicroRNAs and gene targets for OSA management using in silico and in-vitro approach.

Bakshi G, Khurana S, Srivastav S, Kumar R, Chourasia M, Bose S Biotechnol Notes. 2025; 6:79-88.

PMID: 39980971 PMC: 11840522. DOI: 10.1016/j.biotno.2025.01.003.

Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.

Singh J, Adel F, Scott C, Chen H Diabetes Obes Metab. 2024; 27(2):777-784.

PMID: 39587371 PMC: 11905735. DOI: 10.1111/dom.16073.

TongGuanWan Alleviates Doxorubicin- and Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis by Modulating Apoptotic and Fibrotic Pathways.

Yoon J, Tai A, Kim H, Han B, Shin S, Lee H Int J Mol Sci. 2024; 25(19).

PMID: 39408900 PMC: 11476530. DOI: 10.3390/ijms251910573.

Role of dietary inflammatory index in the association of NT-proBNP with all-cause and cardiovascular mortality in NHANES 1999-2004.

Xie L, Liu J, Wang X, Liu B, Li J, Li J Sci Rep. 2024; 14(1):19978.

PMID: 39198638 PMC: 11358152. DOI: 10.1038/s41598-024-70506-3.

Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CSCD-TCM study in China.

Yang T, Zheng H, Pan G, Guo R, Liu F, Liu S Cardiovasc Diabetol. 2023; 22(1):299.

PMID: 37919791 PMC: 10623780. DOI: 10.1186/s12933-023-02015-y.

References

Harris P, Thomas D, Morgan T . Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature. 1987; 326(6114):697-8. DOI: 10.1038/326697a0. View

Engeli S, Birkenfeld A, Badin P, Bourlier V, Louche K, Viguerie N . Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest. 2012; 122(12):4675-9. PMC: 3533552. DOI: 10.1172/JCI64526. View

Rubattu S, Ridker P, Stampfer M, Volpe M, Hennekens C, Lindpaintner K . The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation. 1999; 100(16):1722-6. DOI: 10.1161/01.cir.100.16.1722. View

OConnor C, Starling R, Hernandez A, Armstrong P, Dickstein K, Hasselblad V . Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011; 365(1):32-43. DOI: 10.1056/NEJMoa1100171. View

Cao L, Gardner D . Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995; 25(2):227-34. DOI: 10.1161/01.hyp.25.2.227. View

Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R . N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005; 352(7):666-75. DOI: 10.1056/NEJMoa042330. View

Conen D, Cheng S, Steiner L, Buring J, Ridker P, Zee R . Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study. J Hypertens. 2009; 27(3):476-83. PMC: 2663916. DOI: 10.1097/hjh.0b013e32832104c8. View

Kuhn M . Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004; 99(2):76-82. DOI: 10.1007/s00395-004-0460-0. View

Fleming J, STEINHAUSEN M . Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 1986; 324(6096):473-6. DOI: 10.1038/324473a0. View

10.

Rouleau J, Pfeffer M, Stewart D, Isaac D, Sestier F, Kerut E . Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000; 356(9230):615-20. DOI: 10.1016/s0140-6736(00)02602-7. View

11.

Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M . Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994; 90(1):195-203. DOI: 10.1161/01.cir.90.1.195. View

12.

Veress A, Chong C, Field L, Sonnenberg H . Blood pressure and fluid-electrolyte balance in ANF-transgenic mice on high- and low-salt diets. Am J Physiol. 1995; 269(1 Pt 2):R186-92. DOI: 10.1152/ajpregu.1995.269.1.R186. View

13.

Beige J, Ringel J, Hohenbleicher H, Rubattu S, Kreutz R, Sharma A . HpaII-polymorphism of the atrial-natriuretic-peptide gene and essential hypertension in whites. Am J Hypertens. 1997; 10(11):1316-8. DOI: 10.1016/s0895-7061(97)00305-1. View

14.

Oliver P, John S, PURDY K, Kim R, Maeda N, Goy M . Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. Proc Natl Acad Sci U S A. 1998; 95(5):2547-51. PMC: 19408. DOI: 10.1073/pnas.95.5.2547. View

15.

Gardner D, Chen S, Glenn D, Grigsby C . Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension. 2007; 49(3):419-26. DOI: 10.1161/01.HYP.0000258532.07418.fa. View

16.

Vesely D, Douglass M, Dietz J, Gower Jr W, McCormick M, Schocken D . Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994; 90(3):1129-40. DOI: 10.1161/01.cir.90.3.1129. View

17.

Matsukawa N, Grzesik W, Takahashi N, Pandey K, Pang S, Yamauchi M . The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A. 1999; 96(13):7403-8. PMC: 22098. DOI: 10.1073/pnas.96.13.7403. View

18.

Wang T, Larson M, Levy D, Benjamin E, Leip E, Wilson P . Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109(5):594-600. DOI: 10.1161/01.CIR.0000112582.16683.EA. View

19.

Rubattu S, Evangelista A, Barbato D, Barba G, Stanzione R, Iacone R . Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans. J Hum Hypertens. 2007; 21(10):822-4. DOI: 10.1038/sj.jhh.1002228. View

20.

Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D . Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke. 2004; 35(4):814-8. DOI: 10.1161/01.STR.0000119381.52589.AB. View